Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

Back to Search
Print
Bookmark Trial

NCT00500357

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Amanzimtoti, , 4126, South Africa
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Conjugate Vaccine Vaccines
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65 + years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
NCT00676091
  1. Curitiba,
  2. Florianopolis,
  3. Sau Paulo,
  4. Sau Paulo,
ALL GENDERS
0+
years
MULTIPLE SITES
Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00475033
  1. Calgary, Alberta
  2. Edmonton, Alberta
  3. Coquitlam, British Columbia
  4. Surrey, British Columbia
  5. Vancouver, British Columbia
  6. Winnipeg, Manitoba
  7. Winnipeg, Manitoba
  8. Halifax, Nova Scotia
  9. Montreal, Quebec
  10. Montreal, Quebec
  11. Quebec City, Quebec
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00500357
  1. Amanzimtoti,
  2. Bishop Lavis,
  3. Bloemfontein,
  4. Brits,
  5. Cape Town,
  6. Cape Town,
  7. Lenasia,
  8. Paarl,
  9. Parow,
  10. Parys,
  11. Pretoria,
  12. Pretoria,
  13. Pretoria,
  14. Pretoria,
  15. Scottburgh South,
  16. Vanderbijlpark,
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
NCT00574795
  1. Nagoya-shi, Aichi
  2. Toyohashi-shi, Aichi
  3. Chiba-shi, Chiba
  4. Matsuyama-shi, Ehime
  5. Fukuoka-shi, Fukuoka
  6. Fukuoka-shi, Fukuoka
  7. Fukuoka-shi, Fukuoka
  8. Fukuoka-shi, Fukuoka
  9. Maebaru-shi, Fukuoka
  10. Asahikawa-shi, Hokkaido
  11. Sapporo-shi, Hokkaido
  12. Sapporo-shi, Hokkaido
  13. Sapporo-shi, Hokkaido
  14. Yokohama-shi, Kanagawa
  15. Yokosuka-shi, Kanagawa
  16. Nangoku-shi, Kochi
  17. Ise-shi, Mie
  18. Tsu-shi, Mie
  19. Yokkaichi-shi, Mie
  20. Kurashiki-shi, Okayama
  21. Meguro-ku, Tokyo
  22. Setagaya-ku, Tokyo
  23. Setagaya-ku, Tokyo
  24. Setagaya-ku, Tokyo
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
Official Title  ICMJE A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine Administered to One Group of Individuals Who Participated in Study 6115A1-500
Brief Summary This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to subjects who have already received one dose of 13vPnC, and one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) one year later. This study will determine if a subsequent dose of 13vPnC one year later results in similar or greater immune response (body's ability to protect against disease) than that measured after the initial dose of 13vPnC.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Vaccines, Pneumococcal Conjugate Vaccine
Intervention  ICMJE Biological: 13-valent Pneumococcal Conjugate Vaccine
1 dose 13vPnC
Study Arms  ICMJE Not Provided
Publications * Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Hum Vaccin Immunother. 2014;10(5):1343-53. doi: 10.4161/hv.27998. Epub 2014 Feb 27.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 21, 2011)		105
Original Enrollment  ICMJE
 (submitted: July 10, 2007)		150
Actual Study Completion Date  ICMJE January 2010
Actual Primary Completion Date January 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  • Previous participant of study 6115A1-500 and received 13vPnC +AlPO4 / 23vPS
  • Generally healthy male or female adults 65 years of age or older
  • Available for the duration of the trial - approximately 1 month

  • No history of severe adverse reaction associated with a vaccine

    • MMSE score less than or equal to 21 was an exclusion criteria.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 65 Years and older   (Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE South Africa
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00500357
Other Study ID Numbers  ICMJE 6115A1-3009
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP